ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY.

Autor: Schechet, Sid A., Garff, Kevin, Klima, Karen, Campbell, Wayne, Schocket, Lisa S.
Zdroj: Retinal Cases & Brief Reports; Oct2018, Vol. 12 Issue 4, p307-309, 3p
Abstrakt: Purpose: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor a immunosuppressive therapy. Methods: Case report. Results: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor a antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment. Conclusion: Physicians prescribing tumor necrosis factor a antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index